物流供应商DHL Group收购CRYOPDP，以加强“DHL健康物流”-动脉网

DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

CISION 等信源发布 2025-03-31 21:06



可切换为仅中文







DHL to acquire 100% of CRYOPDP, a leading specialty courier providing logistics services for clinical trials, biopharma, and cell & gene therapies. This acquisition enhances DHL's capabilities in specialty pharma logistics and supports Group's 2030 strategy to become a leader in life science and healthcare logistics..

DHL将收购CRYOPDP的100%股权，这是一家为临床试验、生物制药以及细胞和基因疗法提供物流服务的领先专业快递公司。此次收购增强了DHL在专业医药物流方面的能力，并支持集团到2030年成为生命科学和医疗保健物流领导者的战略。

DHL and Cryoport form strategic partnership to strengthen their respective supply chain services offerings for the global life sciences and healthcare sector.

DHL与Cryoport达成战略合作伙伴关系，以加强各自在全球生命科学和医疗保健领域的供应链服务。

BONN,

波恩，

Germany

德国

and

和

NASHVILLE, Tenn.

纳什维尔，田纳西州

，

March 31, 2025

2025年3月31日

/PRNewswire/ -- DHL Group ('DHL'), the world's leading logistics provider, and

/PRNewswire/ -- 德国邮政敦豪集团（'DHL'），全球领先的物流供应商，和

Cryoport, Inc.

Cryoport公司

(NASDAQ:

（纳斯达克：

CYRX

赛雷克斯

) ('Cryoport'), a global provider of supply chain solutions for the life sciences sector, are pleased to announce that DHL has acquired 100% of CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies. In this context, the companies also announced a strategic partnership to strengthen their supply chain service offerings for the global life sciences and healthcare sector..

）（'Cryoport'），生命科学领域的全球供应链解决方案提供商，很高兴地宣布DHL已收购了专注于临床试验、生物制药以及细胞和基因疗法的领先特种快递公司CRYOPDP的100%股份。在此背景下，这些公司还宣布了一项战略合作伙伴关系，以加强他们为全球生命科学和医疗保健行业提供的供应链服务。

DHL Group already has an established Life Sciences and Healthcare business, contributing over

DHL集团已经建立了生命科学和医疗保健业务，贡献了超过

EUR 5 billion

50亿欧元

in global revenue in 2024. Building on this foundation, the acquisition of CRYOPDP marks a significant step in DHL's commitment to enhancing its capabilities in specialized pharma logistics and expanding the breadth of its offering in the rapidly growing life science and healthcare sector. CRYOPDP specializes in providing white-glove courier services essential to the sectors it serves.

2024年全球收入。基于这一基础，收购CRYOPDP标志着DHL在致力于提升其专业医药物流能力以及扩大其在快速增长的生命科学和医疗保健领域的服务范围方面迈出了重要一步。CRYOPDP专注于为其服务的领域提供至关重要的白手套快递服务。

With operations in 15 countries, CRYOPDP handles over 600,000 shipments per year, servicing customers and patients in over 135 countries worldwide..

CRYOPDP 在15个国家开展业务，每年处理超过60万次运输，为全球135多个国家的客户和患者提供服务。

Going forward, DHL Supply Chain will further build the potential of its Pharma Specialized Network solution by leveraging the specialty courier expertise of newly acquired CRYOPDP and the global air capabilities of DHL Express and DHL Global Forwarding.

未来，DHL供应链将进一步利用新收购的CRYOPDP的专业快递能力以及DHL快递和DHL全球货运的全球航空能力，挖掘其医药专业网络解决方案的潜力。

The strategic partnership with Cryoport will bring together DHL's global health logistics capabilities with Cryoport's industry-leading expertise in providing specialized solutions in a fast growing life science and healthcare market segment. It also deepens DHL's relationship with all the Cryoport business units with respect to specialized pharma..

与Cryoport的战略合作伙伴关系将把DHL的全球健康物流能力与Cryoport在快速增长的生命科学和医疗保健市场领域提供专业解决方案的行业领先专业知识结合起来。这也加深了DHL与Cryoport所有业务部门在专业医药领域的合作关系。

Oscar de Bok

奥斯卡·德·博克

, CEO of DHL Supply Chain, stated, 'The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment.

DHL供应链首席执行官表示：“收购CRYOPDP是我们供应链业务的一项关键举措，我们的目标是扩展我们的医药专业网络，以满足临床试验、生物制药以及细胞和基因治疗不断变化的需求，同时进一步扩大我们在传统制药和生命科学医疗保健领域的影响力。

The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities .'.

收购CRYOPDP并与Cryoport Inc.扩大合作伙伴关系，将使我们能够提供集成的端到端解决方案，增强我们的服务能力。

Jerrell Shelton

杰里尔·谢尔顿

, CEO of Cryoport, commented 'We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced set of supply chain solutions to meet companies' and patients' critical supply chain needs. This strategic partnership taps into the strong expertise of DHL's Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as .

Cryoport首席执行官评论道：“我们确实很高兴能够加强与DHL集团的信任关系。通过合作，我们将提供一套增强的供应链解决方案，以满足公司和患者的关键供应链需求。这一战略合作伙伴关系充分利用了DHL供应链和CRYOPDP的强大专业知识，为Cryoport进一步扩展到全球增长市场提供了重要机会。”

Asia Pacific

亚太地区

(APAC) and

（亚太地区）和

Europe

欧洲

，

Middle East

中东地区

and

和

Africa

非洲

(EMEA).'

（欧洲、中东和非洲）。

The acquisition aligns with DHL Group's Strategy 2030, which emphasizes the importance of temperature-controlled networks, first and last mile specialty courier coverage and integrated solutions. CRYOPDP's capabilities will be instrumental in achieving these objectives and help position DHL as a leader in providing comprehensive solutions for the pharma industry.

该收购符合德国邮政敦豪集团的2030年战略，该战略强调了温控网络、首末段专业快递覆盖和综合解决方案的重要性。CRYOPDP的能力将对实现这些目标起到关键作用，并有助于巩固DHL作为制药行业全面解决方案领导者的地位。

This strategic move is also expected to yield cost savings and improve overall service levels, especially leveraging DHL Express and DHL Global Forwarding air capabilities, ultimately enhancing DHL's footprint in the high-value advanced pharma sector..

这一战略举措预计还将节省成本并提高整体服务水平，特别是利用DHL快递和DHL全球货运的航空能力，最终增强DHL在高价值先进制药领域的影响力。

For Cryoport, the partnership with DHL will enable it to better execute its business in EMEA and APAC with a stronger focus on its core business in these regions, creating even greater opportunities to offer highly targeted, top-tier services in answering market demand for its services and products.

对于Cryoport而言，与DHL的合作伙伴关系将使其能够在欧洲、中东、非洲（EMEA）和亚太地区（APAC）更好地开展业务，更加专注于这些区域的核心业务，从而创造更多机会，提供高度针对性的顶级服务，以满足市场对其服务和产品的需求。

。

The deal and the outlined partnership are subject to regulatory approvals.

该交易及概述的合作伙伴关系需经监管机构批准。

On the internet:

在网上：

group.dhl.com/press

关注我们：

twitter.com/DHLglobal

DHL –

The

logistics company for the world

全球物流服务公司

DHL

is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management.

是物流行业的全球领先品牌。我们的DHL部门提供无与伦比的物流服务组合，包括国内和国际包裹递送、电子商务运输和履行解决方案、国际快递、公路、航空和海洋运输以及工业供应链管理。

With about 395,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as 'The logistics company for the world'..

DHL在全球220多个国家和地区拥有约395,000名员工，安全可靠地连接着人们与企业，推动全球可持续贸易流动。凭借针对增长型市场和行业的专业解决方案，包括技术、生命科学与医疗保健、工程、制造与能源、汽车与零售等领域，DHL坚定地定位为“世界的物流公司”。

DHL is part of DHL Group. The Group generated revenues of more than

DHL是DHL集团的一部分。该集团创造了超过

81.8 billion euros

818亿欧元

in 2023. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. DHL Group aims to achieve net-zero emissions logistics by 2050.

2023年，通过可持续的商业实践以及对社会和环境的承诺，该集团为世界做出了积极贡献。DHL集团旨在2050年实现净零排放物流。

About Cryoport, Inc.

关于Cryoport公司

Cryoport, Inc.

Cryoport公司

(Nasdaq:

（纳斯达克：

CYRX

赛尔克斯

), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty.

），是生命科学领域供应链解决方案的全球领导者，专注于细胞和基因疗法。Cryoport通过旨在降低风险并提供确定性的产品和服务，使制造商、合同制造商 (CDMO)、合同研究组织 (CRO)、开发者和研究人员能够顺利开展各自的业务。

We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are 'Enabling the Future of Medicine™' worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management..

我们为生命科学行业提供广泛的供应链解决方案。通过我们包括先进温控包装、信息学、专业生物物流服务、生物存储、生物服务和低温系统在内的关键产品和解决方案平台，我们通过创新的系统、合规的流程以及灵活的卓越供应链管理方法，在全球范围内“助力医学的未来™”。

Our corporate headquarters, located in

我们的企业总部位于

Nashville, Tennessee

田纳西州纳什维尔

, is complemented by over 50 global locations in 17 countries, with key sites in

，由遍布17个国家的50多个全球地点作为补充，其中关键地点位于

the United States

美国

，

United Kingdom

英国

，

France

法国

，

the Netherlands

荷兰

，

Belgium

比利时

，

Portugal

葡萄牙

，

Germany

德国

，

Japan

日本

，

Australia

澳大利亚

，

India

印度

, and

，以及

China

中国

。

For more information, visit

欲了解更多信息，请访问

www.cryoportinc.com

or follow via LinkedIn at

或通过LinkedIn关注 at

https://www.linkedin.com/company/cryoportinc

or @cryoport on X, formerly known as Twitter at

或在X上@cryoport，之前称为Twitter

www.twitter.com/cryoport

for live updates.

实时更新。

Forward-Looking Statements

前瞻性声明

Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

本新闻稿中的声明并非纯粹的历史事实，包括有关Cryoport的意图、希望、信念、预期、陈述、预测、计划或未来预测的声明，根据1995年《私人证券诉讼改革法案》的规定，这些声明属于前瞻性声明。

These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements.

这些前瞻性陈述包括但不限于与Cryoport对出售CRYOPDP及与DHL战略协作未来收益的预期相关的陈述，包括其对未来收入和收入来源的潜在影响。需要特别注意的是，Cryoport的实际结果可能与此类前瞻性陈述中的内容存在重大差异。

Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks.

可能导致实际结果产生重大差异的因素包括但不限于：与不断变化的经济和地缘政治状况、供应链限制、通货膨胀压力、外币波动的影响、产品市场趋势、Cryoport现金流的变化、市场接受风险以及技术开发风险相关的风险和不确定性。

Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the 'Risk Factors' section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements.

Cryoport的业务可能受到其SEC报告中讨论的其他因素的影响，包括其最近提交的Form 10-K和Form 10-Q定期报告中的“风险因素”部分，以及其随后向SEC提交的文件。本新闻稿中包含的前瞻性陈述仅代表本日期的情况，Cryoport提醒投资者不要对这些前瞻性陈述施加过度依赖。

Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release..

除非法律要求，Cryoport否认任何义务，并且不承担更新或修改本新闻稿中任何前瞻性声明的责任。

SOURCE Cryoport, Inc.

来源：Cryoport公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers